Understanding how tumors develop resistance to chemotherapy is a major issue in oncology. When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long lasting. In addition, it has been suggested that TMZ may drive tumor progression in a subset of patients as a result of acquired resistance. Using longitudinal tumor size measurements from 121 patients, the aim of this study was to develop a semi-mechanistic mathematical model to determine whether resistance of LGG to TMZ was more likely to result from primary and/or from chemotherapy-induced acquired resistance that may contribute to tumor progression. We applied the model to a series of patients treated upfront with TMZ (n = 109) or PCV (procarbazine, CCNU, vincristine) chemotherapy (n = 12) and used a population mixture approach to classify patients according to the mechanism of resistance most likely to explain individual tumor growth dynamics. Our modeling results predicted acquired resistance in 51% of LGG treated with TMZ. In agreement with the different biological effects of nitrosoureas, none of the patients treated with PCV were classified in the acquired resistance group. Consistent with the mutational analysis of recurrent LGG, analysis of growth dynamics using mathematical modeling suggested that in a subset of patients, TMZ might paradoxically contribute to tumor progression as a result of chemotherapy-induced resistance. Identification of patients at risk of developing acquired resistance is warranted to better define the role of TMZ in LGG. 
A B S T R A C T
Understanding how tumors develop resistance to chemotherapy is a major issue in oncology. When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long lasting. In addition, it has been suggested that TMZ may drive tumor progression in a subset of patients as a result of acquired resistance. Using longitudinal tumor size measurements from 121 patients, the aim of this study was to develop a semi-mechanistic mathematical model to determine whether resistance of LGG to TMZ was more likely to result from primary and/or from chemotherapy-induced acquired resistance that may contribute to tumor progression. We applied the model to a series of patients treated upfront with TMZ (n = 109) or PCV (procarbazine, CCNU, vincristine) chemotherapy (n = 12) and used a population mixture approach to classify patients according to the mechanism of resistance most likely to explain individual tumor growth dynamics. Our modeling results predicted acquired resistance in 51% of LGG treated with TMZ. In agreement with the different biological effects of nitrosoureas, none of the patients treated with PCV were classified in the acquired resistance group. Consistent with the mutational analysis of recurrent LGG, analysis of growth dynamics using mathematical modeling suggested that in a subset of patients, TMZ might paradoxically contribute to tumor progression as a result of chemotherapy-induced resistance. Identification of patients at risk of developing acquired resistance is warranted to better define the role of TMZ in LGG.
I N T R O D U C T I O N
Adults' diffuse low-grade glioma (LGG) is a primary brain tumor.
LGGs account for about 25% of gliomas and are characterized radiologically by slow and continuous growth preceding anaplastic transformation [1] . However, despite surgery, radiotherapy, and chemotherapy, most tumors recur and remain incurable with a median survival of 5-15 years. Among chemotherapeutic treatments, temozolomide (TMZ), an alkylating agent, has improved the prognosis of glioblastomas, especially in tumors that have a methylated MGMT promoter and therefore cannot repair TMZ-induced DNA damages [2] . In LGG, however, despite the presence of a methylated MGMT promoter in most patients, the benefit of TMZ remains unclear [3] . Growth kinetic studies have shown that TMZ most frequently results in an initial volume decrease but that this effect is rarely long lasting with most patients developing tumor progression either during or shortly after TMZ disruption [4] . In addition, mutational analyses in recurrent LGG have demonstrated that, in a subset of patients, TMZ leads to the acquisition of a hypermutation phenotype which is associated with increased mitotic activity and could contribute to malignant progression through mutations in the RB and AKT-mTOR pathways [5] . This phenomenon is thought to result from inactivating mutations of the DNA mismatch repair (MMR) pathway which has been shown to be a mechanism of acquired resistance to TMZ, especially in gliomas with a methylated MGMT promoter [6] [7] [8] [9] [10] . Therefore, in a subset of LGG, the mutagenic effect of TMZ could induce inactivating mutations in MMR genes resulting in acquired resistance to TMZ and in a detrimental hypermutation phenotype as a result of continued TMZ exposure [6] .
Mechanisms of LGG resistance to TMZ remain unclear, although we can suppose that two types of resistance exist: (i) primary resistance and (ii) acquired resistance. Primary resistance may correspond to natural tumor capacity to resist to treatment damages, such as p53 mutation and MGMT hypermethylation. As for acquired resistance, it corresponds to genetic and epigenetic changes in neoplastic cells initially sensitive to treatment. Acquired resistance arises with TMZ treatment and can be linked to MGMT production increase [11] or to new mutations appearing after TMZ onset [5, 7] . Nevertheless, these hyper mutated recurrent cancer cells are not observed in all patients treated with TMZ, and there is currently no available pre-TMZ treatment biomarker that can help to prevent this emergence of resistance. Understanding how LGG develop resistance to treatment is therefore a major issue.
Our aim herein is to propose a semi-mechanistic model, describing the different processes of emergence of resistance for LGG treated with TMZ. In this view, our mathematical model distinguishes between sensitive cells, primary resistant cells, and cells becoming resistant due to exposure to treatment. We furthermore present a statistical population mixture model that allows to determine whether a given patient developed acquired resistance or not. Associations between predicted resistance profiles, LGG molecular characteristics and outcome are then studied. To explore whether the resistance profile might be different in patients treated with PCV chemotherapy (procarbazine, CCNU, vincristine), another chemotherapy regimen used in LGG, a subset of patients who received this treatment is also analyzed.
M A T E R I A L S A N D M E T H O D S

Data
We analyzed longitudinal follow-up of tumor size measurements in 121 patients treated with upfront chemotherapy (109 patients with TMZ, 12 patients with PCV) and in whom time-course of tumor size was available before, during, and after treatment [12] . Tumor sizes were expressed as mean tumor diameters (MTDs) estimated from magnetic resonance imaging (MRI) [12] . MRIs were performed every 4-6 months before and after treatment. During the treatment, MRIs were performed every 3 months. For each patient, 12 MRIs were performed on averaged, with at least two MRI before treatment onset and four after. One In most patients, TMZ resulted in an initial reduction in tumor size, which was followed by tumor regrowth either during treatment or after TMZ administration. Figure 1 displays three different individual profiles that are observed in our population of patients treated with TMZ, where duration of treatment is represented with the gray shaded area. The left graph represents an example of a patient who experienced tumor progression during treatment. For the two other patients, the tumor regrows immediately after treatment disruption (middle graph) and after a certain time (right graph). Note that no tumor regrowth during PCV treatment was observed, but rather a prolonged response for several months after cessation of treatment.
In addition to tumor size measurements, data on survival and genetic information were also available for patients treated with TMZ. Progression-free and overall survivals (OSs) were computed as the time between treatment onset and clinical progression or death, respectively. Patients lost to follow-up were censored at the time of last news. For 71 of the 109 patients treated with TMZ, the following molecular characteristics were available: 1p/19q chromosomal codeletion, p53 overexpression, and IDH mutation status. MGMT promoter methylation was available in 53 patients.
Mathematical models for resistance in low-grade gliomas treated with chemotherapy We first developed two models describing each of them a different resistance profile. The first model, called model PR, describes LGG dynamics assuming there are only primary resistant cells. The second model, called model PAR, describes LGG dynamics assuming both primary and acquired resistant cells are present in the tumor. These two models are schematically represented in Figure 2 .
For model PR, we assume that the tumor is initially composed of sensitive cells, denoted S, and primary resistant cells, denoted R P . During treatment, chemotherapy induces DNA lesions to sensitive cells only. They then become damaged cells (denoted D) with a rate s SD C(t), where C(t) is the chemotherapy blood concentration. Damaged cells eventually die with a rate l D . We assume that sensitive and primary resistant cells proliferate with the same growth rate k. Mathematical formulation of this model is as follows:
where P PR = S + D + R P is the total tumor size, P 0 is the initial MTD and k S represents the initial proportion of sensitive cells in the tumor. The tumor is assumed to grow according to a logistic model with maximal tumor size fixed to 120 mm, a choice consistent with the maximal tumor size observed in clinical practice [4] . For TMZ, blood concentration C is supposed to follow a mono-compartmental kinetic [13] :
where k a , Cl, and V are, respectively, the absorption coefficient, the clearance, and the volume of distribution of TMZ. Other ways to implement TMZ concentration would have been possible. For example, the TMZ concentration could have been supposed to be constant during the treatment period. However, this hypothesis seemed to us less realistic than to use a previously published PK model to simulate TMZ concentrations. In addition assuming a continuous TMZ concentration may have introduced a bias in parameters estimate. For PCV, we did not model the three drugs separately. Following the work of Ribba et al. [14] , we defined PCV's concentration C(t) as a unique variable representing a virtual drug administrated intravenously at a dose D fixed to 1:
where k e is the rate of decay of PCV concentration. For model PAR, we assumed that resistant cells emerge due to exposure to chemotherapy, in addition to pre-existing resistant cells. As in model PR, the tumor is initially composed of sensitive cells S and primary resistant cells R P , only sensitive cells being affected by the treatment. However, in this model, damaged cells D can either die with a rate l or become resistant with a rate s DR due to new mutations for instance. These resistant cells, denoted R A in the model, proliferate at a rate k R . Mathematical formulation is as follows:
where P PAR = S + D + R P + R A represents the total tumor size. Because TMZ can induce malignant transformation, and thus faster tumor growth [5] , we further assumed that acquired resistant cells divide at a rate that could be greater than or equal to k. Therefore, we set k R = k(1 + Δ R ), with Δ ≥ 0. Blood concentration of chemotherapy is modeled as described above.
Population mixture model
As hypermutation phenotype was not clinically observed in all patients treated with TMZ, we could Let us denote by y ij tumor measurement at time t ij for the ith patient and / i its individual parameters. We introduce a between-subject model mixture (BSMM) describing tumor observations as follows [15] :
where G i is the resistance profile of patient i, and P PR and P PAR are the tumor size obtained with models (1) and (2), respectively. Residual errors e ij are assumed to be normally distributed with mean equal to 0, and standard deviation equal to r. To summarize equation (3), the BSMM assumes that the growth curve of each subject follows one of the two previously described models (PR or PAR) but without knowing which one a priori. The proportion of the population associated to each of the two models is unknown a priori. Each subject has a label G i corresponding to the model from which it has been generated. This label is inferred using an estimation algorithm. This estimated label is the used to classify the subjects in the two groups. This mixture model enables to describe both patients with primary resistance only and patients who develop acquired resistance within the same model. Such statistical model has been successfully used to detect nonresponder to a given treatment [15, 16] or to describe complex absorption process [17] . Finally, the vector of individual parameters / i was given by
We assumed that all parameters were log-normally distributed, except k S that was assumed to follow a logit-normal distribution.
Model development and evaluation
Model development was based on TMZ data set as the model's hypothesis are based on biological results obtained from patients treated with TMZ. During this first step, we determined which model structure best fitted the data between P PR , P PAR , or BSMM. Once a model's structure was selected, final estimates were obtained using TMZ and PCV data sets that had been pooled together to study potential differences between TMZ-and PCV-treated patients.
Population parameters were estimated using the SAEM algorithm [18] implemented in the Monolix software [19] . Model evaluation and selection were based on the visual inspection of the goodness of fit plots, precision of parameter estimates, and a decrease in Bayesian information criterion (BIC). Shrinkage of individual random effects and residual error was also assessed [20] . The goodness of fit was established by plotting the population predictions of the model vs. observations, individual predictions vs. observations and visual predictive check. All graphics were generated using the package ggplot2 [21] with R software [22] .
Analysis of clusters' characteristics for patients treated by TMZ
When considering the mixture model, each patient is assigned to a cluster. Patients' characteristics of both clusters are compared using a Student's t-test for continuous variables and a chi-squared test for categorical ones. Progression-free survival (PFS) and OS are studied using the Kaplan-Meier method. Difference between PFS and OS in both clusters is assessed using a Logrank test. A multivariate survival analysis is conducted using a Cox proportional hazard model to adjust for age, mutation status, and tumor size at TMZ onset. Statistical significance of each variable is assessed using a Wald test.
R E S U L T S
Model development and evaluation
We first studied whether resistance to TMZ most likely results from primary resistance only (model PR) or from primary and acquired resistance (model PAR). For this purpose, we independently estimated parameters of models PR and PAR on the TMZ data set only. Parameter s SD , standing for the rate of transition from sensitive cells to damaged ones, was considered as fixed effect as it improved the quality of parameter estimates and had no impact on the goodness of fit plots. Moreover it prevents identifiably issues due to the lack of pharmacokinetic data. We found that model PAR performs better than model PR (BIC = 7489 compared to Resistance to temozolomide in gliomas 7670 with model PR), showing that taking into account the two types of resistance more accurately describes experimental data than taking into account primary resistance only.
However, because all tumors do not exhibit hyper mutation phenotype after TMZ treatment [5] and therefore may not develop acquired resistance, we investigated whether model PAR is suitable for all patients. For this purpose, we estimated parameters of the mixture model, which allows patients to be described either with model PR or with model PAR. This latter yielded to even better results suggesting that resistance to TMZ in LGG is variable, resulting from primary resistance only in some patients and from both (primary and acquired resistance) in others. The BSMM mixture model improved data fitting as demonstrated by the decrease in BIC value (BIC = 7466 for BSMM) and led also to a more accurate parameter estimates and a decrease in variances of random effects. Shrinkage values for parameters s SD and Δ R remained high (between 45 and 60%), indicating an identifiably issue in individual random effects. In consequence, no interindividual variability was allocated to these two parameters. It improved shrinkage values and precision of parameter estimates.
After having identified the BSMM model as the model that best fits data in LGG patients treated with upfront TMZ, we estimated parameters of the BSMM model using the whole data set of patients (i.e., including also patients treated with upfront PCV chemotherapy). Population parameter estimates (mean value and interindividual variability) are presented in Table I . Note that as Δ R was estimated different to zero, it implies a faster proliferation of acquired resistant cells, which support the hypothesis of increased mitotic activity. All parameters were accurately estimated with residual standard errors smaller than 25%. Highest shrinkage value of individual random effects was 31%. Shrinkage value of residual errors was 14% indicating good identifiably of the proposed model. Individual parameters were then estimated. In the same time, the 121 patients were classified into one of the two clusters, according to the mechanism of resistance (primary resistance only or primary and acquired resistance) most likely to explain their individual tumor growth dynamics. Among patients treated with upfront TMZ, 56 patients (51%) were assigned to PAR cluster (primary and acquired resistance) and 53 patients (49%) to PR cluster. In contrast, all patients treated with upfront PCV were assigned to PR cluster. Model validation was then performed using observed vs. predicted plots and visual predictive check (VPC). These are presented in Figures 3 and 4 . Concerning VPC plots in TMZ-treated patients, left plot represents VPC for PR cluster, while right plot is VPC for PAR cluster. Data fall into confidence intervals for both clusters, indicating good properties of the population model. Tumor regrowth occurs sooner in the PAR cluster, and tumor size increases faster after TMZ onset. For both cluster, the 95th quantiles seem to over predict tumor regrowth. This phenomenon is partially due to missing information as a consequence of an informative censoring process. Indeed, the follow-up of most patients ended quickly after tumor regrowth because of the initiation of a new therapeutic. Figure 5 displays examples of individual fits for patients in each cluster, with dynamics of each subpopulation of cells. As shown, the model is able to reproduce different patterns of growth dynamics in each cluster.
Impact of genetic mutations and survival analysis
There was no significant difference between baseline characteristics of patients clustered in PR or PAR profile, including age, tumor size at TMZ onset, sex, p53 expression, IDH mutation status, 1p/19q codeletion status, and MGMT methylation status. However, their outcome was different ( Figure 6 ). Patients with acquired resistance to TMZ have both a shorter median PFS (22.7 months (95% CI = 16.0-28.6) vs. 49 months (95% CI = 37.9-57.2), Pvalue < 0.001) and a shorter median OS (50.7 months (95% CI = 35.3-76.4) vs. 139.5 months (95% CI = 86.4 to not reached), P-value < 0.001) compared to patients without acquired resistance. This result is coherent with the model's assumption as acquired resistance enhance tumor growth. On multivariate analysis, the impact of acquired resistance to TMZ was independent of age, molecular profile (p53 overexpression, IDH mutation, and 1p/19q codeletion), and Resistance to temozolomide in gliomas tumor size at TMZ onset (Table II and right plot in Figure 6 ).
D I S C U S S I O N
It has been recently suggested that because of acquired resistance, TMZ may paradoxically drive tumor progression in LGG [5, 6] . Consistently, in the present study, using mathematical modeling, we show that in a subset of LGG, tumor growth dynamics is best described by the hypothesis of a detrimental TMZinduced resistance and that this phenomenon is associated with worst outcome independently of classical prognostic factor. Resistance to treatments is one of the main causes of therapeutic failures in oncology. Mathematical modeling has been shown to be an effective strategy to investigate resistance mechanisms to chemotherapy and to propose new therapeutic strategies [23, 24] . There is a long tradition of mathematical modeling of both resistance to chemotherapy and of glioma growth; however, to the best of our knowledge, no study has specifically focused on modeling resistance to chemotherapy in LGG. Most of the models that have been proposed to describe and analyze cancer resistance to chemotherapy have considered the tumor as being composed of two cell populations: one population of sensitive cells and one population of resistant cells. In the 1980s, [25] first proposed such a model based on ODE. This pioneering model effectively accounted for kinetic resistance in breast cancer treated with cell cycle phase-specific chemotherapy based on the distinction of sensitive/resistant and proliferative/quiescent cells. Thereafter, this framework was widely used to explore different hypotheses in cancer resistance such as optimal dosing schedules and the potential implications of cancer stem cells in drug resistance [23, 26] . However, these models were not developed to explicitly differentiate primary from acquired resistance. For this purpose, Komarova [27] proposed a discrete space Markov process but, this model was not calibrated using clinical data and may be computationally very demanding. Terranova et al. [28] proposed an ODE model incorporating different resistant cell subpopulations allowing the description of both primary and acquired resistance. Here again, the model was not calibrated using real data. Finally, in the specific context of LGG, Mazzocco et al. [29] developed a tumor growth inhibition model of LGG treated with TMZ, in which parameters were estimated using longitudinal tumor size measurements. In this model, however, resistance to TMZ was described using an empirical parametric function, giving no insight on resistance mechanisms, as treatment efficacy was simply considered to decrease with time.
The aim of our study was to develop a model to investigate TMZ resistance in LGG. To our knowledge, this is the first study trying to classify patients according to their potential resistance mechanisms. For this purpose, we developed a model describing both primary and chemotherapy-induced resistance using a data-driven approach. We distinguished different cell subpopulations: sensitive cells, primary resistant cells, damaged cells, and cells that become resistant after being damaged. After evaluating different models, we found that, in agreement with the hypothesis of a detrimental TMZ-driven progression in a subset of patients, the model that most accurately described the data was a model considering that resistance to TMZ in LGG is heterogeneous, consisting of either primary resistance only or primary and acquired resistance contributing to tumor progression. A potential development of the model would be to use it to identify patients who may not benefit from TMZ. However, in the current version of the model, to accurately classify patients, we need observations during and after treatment with TMZ. In order to detect as early as possible patients who develop acquired resistance, or even to predict it, we would need to include covariates such as p53 mutation, IDH mutations or MGMT promoter hypermethylation in the model, particularly on parameter p PAR . In the present study, however, these molecular characteristics were not available in every patients making impossible evaluation of these covariates according to a mixed model approach. Due to the lack of patients who underwent reresection after TMZ progression, we could not determine whether in recurrent tumors clustered with acquired resistance, features suggestive of acquired resistance such as MMR gene mutations or a hypermutation phenotype were found. However, our modeling results are supported by striking similarities with those of the mutational analysis performed in recurrent LGG after TMZ. These analyses have shown that the acquisition of a hypermutation profile after TMZ treatment was only observed in a subset of patients (6 of 10 LGG analyzed [5] ), was associated with an increased mitotic activity and occurred in both LGG with and without the 1p/19q codeletion [5, 30] . Consistently, our model predicted that acquired resistance to TMZ only occurred in a subset of patients (56 of 109 patients), occurred independently of LGG molecular characteristics (especially 1p/19q codeletion), and was associated with a much important growth rate during tumor progression. Our modeling results are also indirectly supported by the fact that none of the patients treated with PCV chemotherapy were classified into the acquired resistance cluster. Indeed, in contrast to TMZ, the effect of CCNU, which is a nitrosourea and the main drug of the PCV regimen, is not mediated by the MMR pathway. To our knowledge, the genomic profile of recurrent LGG after PCV chemotherapy has not been assessed; however, several in vitro studies have shown that in contrast to TMZ, an exposure to nitrosoureas does not lead to the acquisition of a hypermutation phenotype [31] [32] [33] .
Temozolomide-induced hypermutation phenotype has been suggested to be detrimental, but its clinical impact has not been studied yet. It would require the analysis of a large number of reoperated recurrent LGG. Owing to the absence of a biological validation, our model results must be taken with caution, although they suggest that TMZ-induced resistance may have a negative clinical impact. Indeed, in our model, predicted acquired resistance was associated with shorter OS independently of age, tumor size, and of LGG molecular characteristics, namely 1p/19q codeletion. This finding may have important clinical consequences. In recent years, upfront chemotherapy with TMZ has been developed as a strategy to defer radiotherapy and its potential neurotoxicity in LGG patients. The preliminary results of a randomized phase III study comparing initial TMZ vs. initial RT suggested that this strategy might be effective in 1p/19q codeleted but not in LGG without 1p/19q codeletion [3] . Yet, our modeling results suggest that even in 1p/19q codeleted LGG, TMZ might be detrimental in patients at risk of developing acquired resistance.
Although our modeling results provide original insight into the resistance mechanism of LGG after chemotherapy, some points will need to be further investigated. The lack of validation of our prediction is the principal limitation of this work. The validation of our predictions will need (i) to validate at the biological level that our patients with acquired resistance have a hyper mutated phenotype and (ii) to validate our model in an external data set. The association with the worst outcome will also need to be validated in an independent study. Nevertheless, together with mutational analysis of recurrent LGG after TMZ, our study suggests that beyond LGG current molecular classification, the benefit of TMZ may depend on the tumor capacity to develop acquired resistance and that identification of patients at risk of developing acquired resistance will be important to better define the role of TMZ in LGG.
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